系统性红斑狼疮治疗升级后少数患者达到主要临床反应标准
Few meet major clinical response criteria after treatment escalation for lupus
研究发现,系统性红斑狼疮患者在治疗升级后仅23%达到主要临床反应标准,黑人患者尤其不达标,基线时疾病活动度更高、器官损伤更严重。与白人患者相比,黑人患者调整后模型中达到主要临床反应标准的几率更低。研究强调需协调策略解决生物、结构和社会因素导致的不平等结果。
For patients with systemic lupus erythematosus (SLE), fewer than one-quarter meet criteria for major clinical response (MCR) after treatment escalation, with Black patients less likely to meet MCR criteria than white patients, according to a study published online Nov. 2 in The Lancet Rheumatology.
Sarah Dyball, Ph.D., from the University of Manchester in the United Kingdom, and colleagues conducted a longitudinal cohort study to examine the effect of ethnicity on clinical outcomes following treatment escalation. Patients aged 16 years and older with active moderate-to-severe SLE, who had initiated rituximab or belimumab within the past 12 months or standard immunosuppressive therapy within the past one month, were recruited from 64 U.K. secondary and tertiary rheumatology and nephrology centers.
The study included 422 patients: 58%, 18%, 17%, 5% and 3% were white, South Asian, Black, East Asian and of mixed or other ethnicities, respectively. The researchers found that Black patients had higher baseline disease activity, greater organ damage and more comorbidities at baseline.
Overall, 23% of patients had met MCR criteria at 12 months, including 42%, 30%, 24%, 10% and 9% of East Asian, South Asian, white and Black patients, and those of mixed or other ethnicities, respectively. Compared with white patients, patients of Black ethnicity had lower odds of meeting MCR criteria in the adjusted five-group model (odds ratio, 0.13).
"These findings highlight the need for coordinated strategies to address the biological, structural and social determinants underpinning inequitable outcome," the authors write.
Several authors disclosed ties to biopharmaceutical companies, including Roche, GSK and Otsuka, all of which provided funding for the study.
Publication details
Sarah Dyball et al., Effect of ethnicity on response to treatment escalation in patients with systemic lupus erythematosus from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a longitudinal cohort study, The Lancet Rheumatology (2026). DOI: 10.1016/s2665-9913(26)00223-7
Journal information: The Lancet Rheumatology
Clinical categories
Who's behind this story?
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Copyright © 2026 HealthDay. All rights reserved.
Citation: Few meet major clinical response criteria after treatment escalation for lupus (2026, November 9) retrieved 9 November 2026 from https://medicalxpress.com/news/2026-11-major-clinical-response-criteria-treatment.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com